229 related articles for article (PubMed ID: 19568168)
1. Are the pure in situ breast ductal carcinomas and those associated with invasive carcinoma the same?
Schorr MC; Pedrini JL; Savaris RF; Zettler CG
Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):51-4. PubMed ID: 19568168
[TBL] [Abstract][Full Text] [Related]
2. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
3. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
4. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
[TBL] [Abstract][Full Text] [Related]
5. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
6. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
[TBL] [Abstract][Full Text] [Related]
7. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers.
Rehman S; Crow J; Revell PA
Pathol Oncol Res; 2000; 6(4):256-63. PubMed ID: 11173657
[TBL] [Abstract][Full Text] [Related]
8. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
[TBL] [Abstract][Full Text] [Related]
9. Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.
Liu C; Zhang H; Shuang C; Lu Y; Jin F; Xu H; Lu P
Med Oncol; 2010 Sep; 27(3):747-52. PubMed ID: 19657752
[TBL] [Abstract][Full Text] [Related]
10. The extent of proliferative and apoptotic activity in intraductal and invasive ductal breast carcinomas detected by Ki-67 labeling and terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling.
Shen KL; Harn HJ; Ho LI; Yu CP; Chiu SC; Lee WH
Cancer; 1998 Jun; 82(12):2373-81. PubMed ID: 9635530
[TBL] [Abstract][Full Text] [Related]
11. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
[TBL] [Abstract][Full Text] [Related]
12. Oestrogen-induced genes in ductal carcinoma in situ: their comparison with invasive ductal carcinoma.
Ebata A; Suzuki T; Takagi K; Miki Y; Onodera Y; Nakamura Y; Fujishima F; Ishida K; Watanabe M; Tamaki K; Ishida T; Ohuchi N; Sasano H
Endocr Relat Cancer; 2012 Aug; 19(4):485-96. PubMed ID: 22569827
[TBL] [Abstract][Full Text] [Related]
13. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast.
Iwase H; Ando Y; Ichihara S; Toyoshima S; Nakamura T; Karamatsu S; Ito Y; Yamashita H; Toyama T; Omoto Y; Fujii Y; Mitsuyama S; Kobayashi S
Breast Cancer; 2001; 8(2):98-104. PubMed ID: 11342981
[TBL] [Abstract][Full Text] [Related]
15. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
Perrone G; Santini D; Vincenzi B; Zagami M; La Cesa A; Bianchi A; Altomare V; Primavera A; Battista C; Vetrani A; Tonini G; Rabitti C
Histopathology; 2005 May; 46(5):561-8. PubMed ID: 15842638
[TBL] [Abstract][Full Text] [Related]
16. Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer.
Wong H; Lau S; Yau T; Cheung P; Epstein RJ
Br J Cancer; 2010 Apr; 102(9):1391-6. PubMed ID: 20424617
[TBL] [Abstract][Full Text] [Related]
17. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of the erbB2 and hormone receptor status of neighboring invasive and in situ components of ductal carcinomas of the breast.
Peres RM; Serra KP; Derchain SF; Yoon JH; Pinto GA; Alvarenga M; Soares FA; Heinrich JK; da Cunha IW; Vassallo J; Sarian LO
Int J Biol Markers; 2009; 24(4):238-44. PubMed ID: 20108215
[TBL] [Abstract][Full Text] [Related]
19. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
Bartova M; Ondrias F; Muy-Kheng T; Kastner M; Singer Ch; Pohlodek K
Bratisl Lek Listy; 2014; 115(7):445-51. PubMed ID: 25077370
[TBL] [Abstract][Full Text] [Related]
20. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems.
Leong AS; Sormunen RT; Vinyuvat S; Hamdani RW; Suthipintawong C
Am J Clin Pathol; 2001 May; 115(5):709-18. PubMed ID: 11345835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
